Coloplast A/S (OTCMKTS:CLPBY) Raised to Strong-Buy at Barclays

Coloplast A/S (OTCMKTS:CLPBY) was upgraded by Barclays from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Tuesday, Zacks reports.

Coloplast A/S Price Performance

Shares of OTCMKTS CLPBY opened at $7.80 on Tuesday. The firm has a market cap of $17.59 billion, a P/E ratio of 37.16, a price-to-earnings-growth ratio of 2.85 and a beta of 0.10. The company has a current ratio of 1.56, a quick ratio of 0.94 and a debt-to-equity ratio of 1.51. Coloplast A/S has a 1-year low of $5.64 and a 1-year high of $9.57. The business’s 50 day moving average is $6.85 and its 200-day moving average is $6.79.

Coloplast A/S (OTCMKTS:CLPBY) last released its quarterly earnings results on Tuesday, November 3rd. The company reported $0.09 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.09. The business had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.12 billion. Coloplast A/S had a return on equity of 42.25% and a net margin of 10.57%. Equities research analysts predict that Coloplast A/S will post 0.40 earnings per share for the current year.

About Coloplast A/S

Coloplast A/S is a Denmark-based medical technology company that develops, manufactures and markets products designed to help people manage intimate health conditions. Its core businesses include ostomy care, continence care, wound and skin care, and interventional urology. The company’s products are used by patients and healthcare professionals in hospitals, clinics and home-care settings.

Coloplast was founded in Denmark in 1957 after nurse Elise Sørensen helped develop an adhesive ostomy bag for her sister, who had undergone surgery.